Last 12 months
Inside the activity.
0 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2020 Filed Feb 18, 2020 19:38 UTC |
Kuipers Peter J.Executive V P& CFO
|
Exercise / conversionCommon Stock | 11,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001738 · edgar.xml · nonDerivative · entry 4 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,285 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 18, 2020 19:39 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
GiftCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001739 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · In Trust with Wife Disclosed balance after: 269,409 F3 · shares: Gifted shares from founders 15,000 shares to Donor Advised Fund. F1 · ownership.nature: Shares held in trust with Mr. Lipps' wife. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:38 UTC |
Kuipers Peter J.Executive V P& CFO
|
GrantStock Options NQ (Right to Buy) · Derivative | 25,618 | $0.00 Strike: $90.19 | $0.00 |
DisclosureSEC source: 0001179110-20-001738 · edgar.xml · derivative · entry 7 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,618 Underlying: Common Stock · 25,618 shares Expires 2030-02-12 F3 · shares: NQ: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:38 UTC |
Kuipers Peter J.Executive V P& CFO
|
GrantCommon Stock | 5,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001738 · edgar.xml · nonDerivative · entry 3 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,018 F2 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:38 UTC |
Kuipers Peter J.Executive V P& CFO
|
GrantCommon Stock | 6,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001738 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,031 F1 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2021 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2021 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:39 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
GrantStock Options NQ (Right to Buy) · Derivative | 25,618 | $0.00 Strike: $90.19 | $0.00 |
DisclosureSEC source: 0001179110-20-001740 · edgar.xml · derivative · entry 4 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,618 Underlying: Common Stock · 25,618 shares Expires 2030-02-12 F3 · shares: NQ: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:39 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
GrantCommon Stock | 5,987 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001740 · edgar.xml · nonDerivative · entry 3 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,281 F2 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:39 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
GrantCommon Stock | 6,653 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001740 · edgar.xml · nonDerivative · entry 2 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,294 F1 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2021 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2021 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:39 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
GrantStock Options NQ (Right to Buy) · Derivative | 89,874 | $0.00 Strike: $90.19 | $0.00 |
DisclosureSEC source: 0001179110-20-001739 · edgar.xml · derivative · entry 6 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,874 Underlying: Common Stock · 89,874 shares Expires 2030-02-12 F5 · shares: NQ: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:39 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
GrantCommon Stock | 42,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001739 · edgar.xml · nonDerivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,266 F4 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2021 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2021 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:38 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
GrantStock Options NQ (Right to Buy) · Derivative | 8,537 | $0.00 Strike: $90.19 | $0.00 |
DisclosureSEC source: 0001179110-20-001737 · edgar.xml · derivative · entry 4 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,537 Underlying: Common Stock · 8,537 shares Expires 2030-02-12 F3 · shares: NQ: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:38 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
GrantCommon Stock | 1,996 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001737 · edgar.xml · nonDerivative · entry 3 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,051 F2 · shares: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:38 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
GrantCommon Stock | 2,218 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001737 · edgar.xml · nonDerivative · entry 2 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,055 F1 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2021 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2021 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:38 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
GrantStock Options NQ (Right to BUY) · Derivative | 17,077 | $0.00 Strike: $90.19 | $0.00 |
DisclosureSEC source: 0001179110-20-001736 · edgar.xml · derivative · entry 4 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,077 Underlying: Common Stock · 17,077 shares Expires 2030-02-12 F2 · shares: NQ: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:38 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
GrantCommon Stock | 3,992 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001736 · edgar.xml · nonDerivative · entry 3 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,639 F3 · price: RSU: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:38 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
GrantCommon Stock | 4,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001736 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,647 F1 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2021 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2021 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. F1 · price: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2021 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2021 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 17:16 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 2,833 | $0.00 Strike: $43.30 | $0.00 |
DisclosureSEC source: 0001179110-20-001435 · edgar.xml · derivative · entry 6 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,833 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 17:16 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
SaleCommon Stock | 584 | $87.31 | $50,986.82 |
DisclosureSEC source: 0001179110-20-001435 · edgar.xml · nonDerivative · entry 5 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,641 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F4 · price: The price reported in Column 4 is the average price of $87.3062. The sold price range between $87.16 to $87.45. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 17:16 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
SaleCommon Stock | 1,649 | $86.58 | $142,767.45 |
DisclosureSEC source: 0001179110-20-001435 · edgar.xml · nonDerivative · entry 4 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,225 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F3 · price: The price reported in Column 4 is the average price of $86.5782. The sold price range between $86.07 to $87.04. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 17:16 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
SaleCommon Stock | 600 | $84.91 | $50,943.96 |
DisclosureSEC source: 0001179110-20-001435 · edgar.xml · nonDerivative · entry 3 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,874 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F2 · price: The price reported in Column 4 is the average price of $84.9066. The sold price range between $84.58 to $85.42. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 17:16 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 2,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-001435 · edgar.xml · nonDerivative · entry 2 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| January 07, 2020 Filed Jan 8, 2020 21:28 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionStpck Options NQ (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $27.70 | $0.00 |
DisclosureSEC source: 0001179110-20-000416 · edgar.xml · derivative · entry 9 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2020 Filed Jan 8, 2020 21:28 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 2,568 | $82.11 | $210,850.01 |
DisclosureSEC source: 0001179110-20-000416 · edgar.xml · nonDerivative · entry 8 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,466 F7 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F5 · price: The price reported in Column 4 is the average price of $82.1067. The sold price range between $81.84 to $82.71. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2020 Filed Jan 8, 2020 21:28 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 21,432 | $81.33 | $1,743,002.41 |
DisclosureSEC source: 0001179110-20-000416 · edgar.xml · nonDerivative · entry 7 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,034 F7 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F6 · price: The price reported in Column 4 is the average price of $81.3271. The sold price range between $80.83 to $81.83. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 07, 2020 Filed Jan 8, 2020 21:28 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-000416 · edgar.xml · nonDerivative · entry 6 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| January 07, 2020 Filed Jan 8, 2020 21:28 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 400 | $82.11 | $32,845.00 |
DisclosureSEC source: 0001179110-20-000416 · edgar.xml · nonDerivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · In Trust with Wife Disclosed balance after: 284,409 F7 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F4 · price: The price reported in Column 4 is the average price of $82.1125. The sold price range between $82.03 to $82.22. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: Shares held in trust with Mr. Lipps' wife. Read SEC document |
| January 07, 2020 Filed Jan 8, 2020 21:28 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 4,600 | $81.37 | $374,297.86 |
DisclosureSEC source: 0001179110-20-000416 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · In Trust with Wife Disclosed balance after: 284,809 F7 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F3 · price: The price reported in Column 4 is the average price of $81.3691. The sold price range between $80.98 to $81.86. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · ownership.nature: Shares held in trust with Mr. Lipps' wife. Read SEC document |
| December 16, 2019 Filed Dec 16, 2019 21:47 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
SaleCommon Stock | 1,356 | $80.59 | $109,281.40 |
DisclosureSEC source: 0001179110-19-012830 · edgar.xml · nonDerivative · entry 2 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,641 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F1 · price: The price reported in Column 4 is the average price of $80.5910. The sold price range between $80.22 to $80.94. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2019 Filed Dec 16, 2019 20:07 UTC |
SPEARS JOSEPH BRIANChief Accounting Officer & VP
|
Tax withholdingCommon Stock | 389 | $79.69 | $30,999.41 |
DisclosureSEC source: 0001179110-19-012783 · edgar.xml · nonDerivative · entry 2 SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,969 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2019 Filed Dec 16, 2019 20:05 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Tax withholdingCommon Stock | 2,778 | $79.69 | $221,378.82 |
DisclosureSEC source: 0001179110-19-012782 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,212 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2019 Filed Dec 16, 2019 20:04 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
Tax withholdingCommon Stock | 1,336 | $79.69 | $106,465.84 |
DisclosureSEC source: 0001179110-19-012780 · edgar.xml · nonDerivative · entry 2 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,997 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2019 Filed Dec 16, 2019 20:05 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Tax withholdingCommon Stock | 12,021 | $79.69 | $957,953.49 |
DisclosureSEC source: 0001179110-19-012781 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,466 F3 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2019 Filed Dec 16, 2019 20:03 UTC |
Kuipers Peter J.Executive V P& CFO
|
Tax withholdingCommon Stock | 3,471 | $79.69 | $276,603.99 |
DisclosureSEC source: 0001179110-19-012778 · edgar.xml · nonDerivative · entry 2 Kuipers Peter J. · CIK 0001651691 · Executive V P& CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,378 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 15, 2019 Filed Dec 16, 2019 20:04 UTC |
Ngo Nhat HEVP, Marketing, S & B D
|
Tax withholdingCommon Stock | 3,484 | $79.69 | $277,639.96 |
DisclosureSEC source: 0001179110-19-012779 · edgar.xml · nonDerivative · entry 2 Ngo Nhat H · CIK 0001305020 · EVP, Marketing, S & B D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,837 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 20:05 UTC |
SPEARS JOSEPH BRIANChief Accounting Officer & VP
|
GrantStock Options NQ (Right to Buy) · Derivative | 7,350 | $0.00 Strike: $79.23 | $0.00 |
DisclosureSEC source: 0001179110-19-012316 · edgar.xml · derivative · entry 3 SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,350 Underlying: Common Stock · 7,350 shares Expires 2029-12-02 F1 · shares: Shares shall vest ratably over 48 month period, with a year cliff.25% vest on 12/3/2020 rest will vest monthly for 36 months. Read SEC document |
| December 03, 2019 Filed Dec 4, 2019 20:05 UTC |
SPEARS JOSEPH BRIANChief Accounting Officer & VP
|
GrantCommon Stock | 2,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-012316 · edgar.xml · nonDerivative · entry 2 SPEARS JOSEPH BRIAN · CIK 0001729964 · Chief Accounting Officer & VP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,358 F2 · shares: Restricted stock units shall vest quarterly from 12/15 and 3/15, 6/15 and 9/15. Read SEC document |
| November 29, 2019 Filed Dec 2, 2019 19:31 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Exercise / conversionStpck Options NQ (Right to Buy) · Derivative | 1,426 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-19-012156 · edgar.xml · derivative · entry 8 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,426 shares Expires 2027-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| November 29, 2019 Filed Dec 2, 2019 19:31 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Exercise / conversionStpck Options NQ (Right to Buy) · Derivative | 4,824 | $0.00 Strike: $27.70 | $0.00 |
DisclosureSEC source: 0001179110-19-012156 · edgar.xml · derivative · entry 7 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,824 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| November 29, 2019 Filed Dec 2, 2019 19:31 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
SaleCommon Stock | 2,836 | $80.30 | $227,730.80 |
DisclosureSEC source: 0001179110-19-012156 · edgar.xml · nonDerivative · entry 6 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,990 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F4 · price: The price reported in Column 4 is the price of $80.30. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 29, 2019 Filed Dec 2, 2019 19:31 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
SaleCommon Stock | 1,426 | $80.30 | $114,507.80 |
DisclosureSEC source: 0001179110-19-012156 · edgar.xml · nonDerivative · entry 5 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,826 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F4 · price: The price reported in Column 4 is the price of $80.30. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 29, 2019 Filed Dec 2, 2019 19:31 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
SaleCommon Stock | 300 | $81.00 | $24,300.00 |
DisclosureSEC source: 0001179110-19-012156 · edgar.xml · nonDerivative · entry 4 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,252 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F3 · price: The price reported in Column 4 is the price of $81.00. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 29, 2019 Filed Dec 2, 2019 19:31 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
SaleCommon Stock | 4,524 | $80.41 | $363,759.91 |
DisclosureSEC source: 0001179110-19-012156 · edgar.xml · nonDerivative · entry 3 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,552 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. F2 · price: The price reported in Column 4 is the average price of $80.4067. The sold price range between $79.97 to $80.90. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 29, 2019 Filed Dec 2, 2019 19:31 UTC |
JOHNSTON DAN SEVP & Chief Legal & Admin
|
Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-012156 · edgar.xml · nonDerivative · entry 2 JOHNSTON DAN S · CIK 0001271802 · EVP & Chief Legal & Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 16:23 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 20,902 | $0.00 Strike: $27.70 | $0.00 |
DisclosureSEC source: 0001179110-19-011995 · edgar.xml · derivative · entry 7 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,902 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 16:23 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 5,280 | $79.25 | $418,430.50 |
DisclosureSEC source: 0001179110-19-011995 · edgar.xml · nonDerivative · entry 6 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,409 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan F5 · price: The price reported in Column 4 is the average price of $79.2482. The sold price range between $79.0250 to $79.39. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 16:23 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
SaleCommon Stock | 15,622 | $78.58 | $1,227,587.70 |
DisclosureSEC source: 0001179110-19-011995 · edgar.xml · nonDerivative · entry 5 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,689 F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan F4 · price: The price reported in Column 4 is the average price of $78.5807. The sold price range between $78.00 to $78.99. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 16:23 UTC |
LIPPS RANDALL ADirector · Chairman, President and CEO
|
Exercise / conversionCommon Stock | 20,902 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-011995 · edgar.xml · nonDerivative · entry 4 LIPPS RANDALL A · CIK 0001227556 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,311 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan Read SEC document |
| November 15, 2019 Filed Nov 15, 2019 22:50 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
Exercise / conversionStock Options NQ (Right to Buy) · Derivative | 2,833 | $0.00 Strike: $43.30 | $0.00 |
DisclosureSEC source: 0001179110-19-011764 · edgar.xml · derivative · entry 4 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,833 shares Expires 2028-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
| November 15, 2019 Filed Nov 15, 2019 22:50 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
SaleCommon Stock | 2,833 | $75.00 | $212,475.00 |
DisclosureSEC source: 0001179110-19-011764 · edgar.xml · nonDerivative · entry 3 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,333 F2 · price: The price reported in Column 4 is the average price of $75.00. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2019 Filed Nov 15, 2019 22:50 UTC |
Seidelmann Scott PeterEVP, Chief Commercial Officer
|
Exercise / conversionCommon Stock | 2,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-011764 · edgar.xml · nonDerivative · entry 2 Seidelmann Scott Peter · CIK 0001736895 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.